Cargando…

1015. Real World Use of Dalbavancin and Oritavancin for Optimized Outpatient Antimicrobial Therapy in Patients Inappropriate for Standard Therapy

BACKGROUND: Dalbavancin and oritavancin are long acting lipoglycopeptide antibiotics (LaLGP) approved for treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive organisms. These antibiotics have shown promise in treatment of non-FDA approved gram...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weichman, Brittani, Bushman, Amanda, Aarhus, Angela, Terrero Salcedo, David A, Drake, Ty C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751981/ http://dx.doi.org/10.1093/ofid/ofac492.856

Ejemplares similares

163. Assessment of Pneumonia FilmArray Use on the Impact on Antimicrobial De-escalation Within an Integrated Health System
por: Weichman, Brittani, et al.
Publicado: (2022)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

754. Evaluation of Standardized Dalbavancin Use to Facilitate Early Hospital Discharge for Patients Inappropriate for Outpatient Parenteral Antibiotic Therapy
por: Shihadeh, Katherine C, et al.
Publicado: (2019)

Vibrational Optical Activity Study of Four Antibiotic (Lipo)glycopeptides: Vancomycin, Oritavancin, Dalbavancin, and Teicoplanin
por: Aerts, Roy, et al.
Publicado: (2022)

613. Clinical Outcomes Following Dalbavancin Administration during Outpatient Parenteral Antimicrobial Therapy
por: Tuan, Jessica, et al.
Publicado: (2021)

Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
por: Tuan, Jessica J., et al.
Publicado: (2022)

Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
por: Koutsari, Christina, et al.
Publicado: (2017)

74. Evaluation of the Differences in Appropriateness of BioFire® FilmArray® Gastrointestinal Panel Testing between Emergency Department and Inpatient Services
por: Weichman, Brittani, et al.
Publicado: (2021)

158. Impact of Fluoroquinolone Cascade Reporting of Urine Samples on Antibiotic Prescribing Rates in a Network of Urgent Care Clinics
por: Weichman, Brittani, et al.
Publicado: (2021)

Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections
por: Stewart, Cassie L., et al.
Publicado: (2017)

234. Dalbavancin versus Outpatient Parenteral Antimicrobial Therapy with Vancomycin for Treatment of Bone and Joint Infections in a Veteran Population
por: Gibbons, Emily A, et al.
Publicado: (2021)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

Impact of fluoroquinolone cascade reporting of urine samples on antibiotic prescribing rates in a network of urgent care clinics
por: Weichman, Brittani M., et al.
Publicado: (2022)

Real-World Use of Oritavancin for the Treatment of Osteomyelitis
por: Scoble, Patrick J., et al.
Publicado: (2020)

P1015: THE EFFECT OF THERAPY ON THE COAGULATION ACTIVITY OF MICROPARTICLES IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Silina, Natalia, et al.
Publicado: (2023)

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections
por: Bork, Jacqueline T., et al.
Publicado: (2019)

Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections
por: Moenster, Ryan P, et al.
Publicado: (2023)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study
por: Anastasio, Patrick J., et al.
Publicado: (2017)

Real-World Evidence for Oritavancin Use in Gram-Positive Infections
Publicado: (2020)

1845. Oritavancin Compared to the Standard-of-Care for the Treatment of Gram-positive Blood Stream Infections
por: Moenster, Ryan P, et al.
Publicado: (2022)

Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis
por: Cain, Alexander R, et al.
Publicado: (2021)

1829. Dalbavancin versus standard of care as directed therapy for Staphylococcus aureus bacteremia in patients unable to receive OPAT
por: Frazier, J, et al.
Publicado: (2022)

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
por: Ajaka, Leama, et al.
Publicado: (2020)

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs
por: Gatti, Milo, et al.
Publicado: (2021)

Clinical Efficacy of Temocillin Standard Dosing in Patients Treated with Outpatient Antimicrobial Therapy
por: Van den Broucke, Evelyne, et al.
Publicado: (2022)

234 Characterization of Inappropriate Antimicrobial Therapy Following Changes in Antimicrobial Stewardship Strategies
por: Pham, Christine, et al.
Publicado: (2014)

Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety
por: Ruiz-Sancho, Andrés, et al.
Publicado: (2023)

1015. A multicenter evaluation of antimicrobial utilization in hospitalized bone marrow transplant (BMT) and T-cell therapy (CAR-T) patients, and the impact on rates of C. difficile infection (CDI)
por: Nagel, Jerod, et al.
Publicado: (2023)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

The Clinical Efficacy of Multidose Oritavancin: A Systematic Review
por: Baiardi, Giammarco, et al.
Publicado: (2023)

Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy
por: Vazquez Deida, Axel A, et al.
Publicado: (2020)

Detection and Characterization of β-Lactam Resistance in Bacillus cereus PTCC 1015
por: Behravan, Javad, et al.
Publicado: (2004)

1015 Facilitators and Barriers to SSI Bundle Implementation in Select Surgical Procedures
por: Reisinger, Heather, et al.
Publicado: (2014)

1015. Antibiotic use and indications in a community sample of adults in Wisconsin
por: Schletzbaum, Maria, et al.
Publicado: (2019)

1286. Evaluating Dalbavancin Suppression Therapy in Patients at High Risk for Recurrent Infections
por: Shaw, Michael, et al.
Publicado: (2023)

OPAT: outpatient parenteral antimicrobial therapy
Publicado: (2020)

Outpatient parenteral antimicrobial therapy in Brazil
por: Oliveira, Priscila R, et al.
Publicado: (2023)

Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis
por: Helton, Brittany, et al.
Publicado: (2020)

Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context
por: De Nicolò, Amedeo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_74squajvbdkb7sih6qeepau7pf